Skip to content

For US Healthcare Professionals Only

Prescribing Information
Patient Site
VEVYEContact Us

WELL-TOLERATEDBy Patients1,5-7

VEVYE® is shown to be well-tolerated and comfortable with 8% of patients experiencing site instillation reactions and 3% reporting a temporary decrease in visual acuity.

WELL-TOLERATEDBy Patients1,5-7By Patients1,5-7

VEVYE® is shown to be well-tolerated and comfortable with 8% of patients experiencing site instillation reactions and 3% reporting a temporary decrease in visual acuity.

99.8%of patients experienced no or
mild instillation site pain5-7

*Total number of patients in pooled data: 785.

99.8% of patients

experienced no or
mild instillation
site pain5-7*

*Total number of patients in pooled data: 785.

Common Adverse Reactions1,5-7

Ocular AEs (Occurring in More Than 2% of Patients)

Ocular adverse events occurring in more than 2% of patientsOcular adverse events occurring in more than 2% of patients

Swipe to view More

Over 3 studies,

VEVYE® (cyclosporine ophthalmic solution) 0.1% had ZERO reports of severe instillation site pain.5‑7

Most common adverse reactions included instillation site reactions (8%) and temporary decrease in visual acuity (3%). 

In a 52-week extension study

Only 1 patient discontinued treatment

due to an ocular adverse event (mild burning/stinging). (n=202)7

Discontinuation Rates4-7

Discontinuation rates by treatmentDiscontinuation rates by treatment

Swipe to view More

**Treatment Emergent Adverse Event (TEAE) suspected to be related to VEVYE.

A runner

time to try vevye

Connect with a representative to learn more.

Connect with a representative to learn more.

Contact Us
A runner

INDICATION AND USAGE

VEVYE® (cyclosporine ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

  • Potential for Eye Injury and Contamination – To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces.
  • Use with Contact Lenses – VEVYE should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following the administration of VEVYE.

Adverse Reactions

In clinical trials with 738 subjects receiving at least 1 dose of VEVYE, the most common adverse reactions were instillation site reactions (8%) and temporary decreases in visual acuity (3%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
For additional information about VEVYE, please see the Full Prescribing Information.

INDICATION AND USAGE

VEVYE® (cyclosporine ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

  • Potential for Eye Injury and Contamination – To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces.
  • Use with Contact Lenses – VEVYE should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following the administration of VEVYE.

Adverse Reactions

In clinical trials with 738 subjects receiving at least 1 dose of VEVYE, the most common adverse reactions were instillation site reactions (8%) and temporary decreases in visual acuity (3%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For additional information about VEVYE, please see the Full Prescribing Information.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

  • Potential for Eye Injury and Contamination – Patients should not touch the bottle tip to the eye or other surfaces.
  • Use with Contact Lenses – VEVYE should not be administered while wearing contact lenses. If worn, lenses should be removed prior to administration and may be reinserted 15 minutes following the administration of VEVYE.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

  • Potential for Eye Injury and Contamination – Patients should not touch the bottle tip to the eye or other surfaces.